Implementing a same-day PCI discharge pathway boils down to correct patient selection

With advances and increased experience in percutaneous coronary intervention (PCI), same-day discharge (SDD) has become increasingly commonplace. However, the Society for Cardiovascular Angiography and Interventions (SCAI) said patient selection is crucial to success.

SDD can provide many benefits to patients and health systems and has become the predominant model of care following an elective PCI, SCAI detailed in its February "Quality Improvement Tips of the Month." An outline for keeping these procedures safe is explained by authors Maximillian Bourdillon, MD; Konstantinos Charitakis, MD, FSCAI; and Konstantinos Dean Boudoulas, MD, FSCAI.

They said the advantages of SDD include improved patient satisfaction when compared to routine overnight monitoring and reduced nosocomial infections and hospital-associated adverse events, such as falls. There is also an associated cost benefit to the health system with improved bed capacity and hospital throughput. There also would be an estimated savings of $200-$500 million if half of U.S. patients undergoing elective PCI used SDD. They pointed out that rates of SDD are rising, and there has not been any associated increase in adverse outcomes.

Selecting the right PCI patients for same day discharge

These are the key points when considering which patients are ideal for SDD:

  • Any nonurgent, outpatient PCI can be considered for SDD. Patients presenting with acute coronary syndrome need closer monitoring, but staged procedures at the end of a hospitalization to completed revascularization of a nonculprit lesion might also be considered, the authors explained. It really boils down to the complexity of the intervention, they said. 
  • Patients should have adequate home caregiver support to stay with the patient overnight following discharge, help with activities of daily living, and aid with access to emergency services, if needed. 
  • Patients are identified by the operator pre-procedure, based on procedural and anatomic considerations and the patient’s choice to proceed with SDD. 
  • After PCI, reassessment of the patient should be performed to ensure they still qualify for SDD. This includes successful PCI without complications, routine post-procedure vascular access site monitoring, patients’ clinical status, and evaluation for evidence of stroke or changes in mental status, bleeding, allergic reactions, angina, heart failure, ECG changes, arrhythmia, or exacerbation of chronic medical conditions.
  • Pre-procedure and post-procedure checklists are highlighted in the 2021 American College of cardiology (ACC) Expert Consensus Decision Pathway to identify patient suitability for SDD pre-procedure, post-PCI, and pre-discharge. 

Read the SCAI article for more details

Dave Fornell is a digital editor with Cardiovascular Business and Radiology Business magazines. He has been covering healthcare for more than 16 years.

Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.